{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:00:31Z","timestamp":1791406831987,"version":"4.3.3"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jgar.2021.02.031","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T04:38:20Z","timestamp":1616128700000},"page":"93-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016\u20132018 from USA and Europe: genotypic analysis of \u03b2-lactamases and comparative in vitro activity of cefepime\/enmetazobactam"],"prefix":"10.1016","volume":"25","author":[{"given":"Adam","family":"Belley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Morrissey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hawser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimmi","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Knechtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.02.031_bib0001","doi-asserted-by":"crossref","first-page":"e01076","DOI":"10.1128\/AAC.01076-18","article-title":"Past and present perspectives on \u03b2-lactamases","volume":"62","author":"Bush","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.02.031_bib0002","doi-asserted-by":"crossref","first-page":"e969","DOI":"10.1016\/S2214-109X(18)30278-X","article-title":"Estimating the number of infections caused by antibiotic-resistant Escherichia coli and Klebsiella pneumoniae in 2014: a modelling study","volume":"6","author":"Temkin","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jgar.2021.02.031_bib0003","series-title":"Antibiotic resistance threats in the United States","year":"2019"},{"key":"10.1016\/j.jgar.2021.02.031_bib0004","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1914433","article-title":"Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012\u20132017","volume":"382","author":"Jernigan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2021.02.031_bib0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2021.02.031_bib0006","series-title":"Global priority list of antibiotic-resistant bacteria to guide research, discovery and development of new antibiotics","year":"2017"},{"key":"10.1016\/j.jgar.2021.02.031_bib0007","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3390\/antibiotics4040653","article-title":"Examining the clinical effectiveness of non-carbapenem \u03b2-lactams for the treatment of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"4","author":"Gibble","year":"2015","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2021.02.031_bib0008","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.cmi.2019.03.030","article-title":"Current options for the treatment of infections due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in different groups of patients","volume":"25","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2021.02.031_bib0009","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: past, present, and future","volume":"55","author":"Papp-Wallace","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2021.02.031_bib0010","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/ofid\/ofy347","article-title":"Variations in the occurrence of resistance phenotypes and carbapenemase genes among Enterobacteriaceae isolates in 20 years of the SENTRY antimicrobial surveillance program","volume":"6","author":"Castanheira","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2021.02.031_bib0011","doi-asserted-by":"crossref","first-page":"e17157","DOI":"10.1097\/MD.0000000000017157","article-title":"Antimicrobial resistance surveillance and prediction of Gram-negative bacteria based on antimicrobial consumption in a hospital setting: a 15-year retrospective study","volume":"98","author":"Guo","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jgar.2021.02.031_bib0012","doi-asserted-by":"crossref","first-page":"e13719","DOI":"10.1097\/MD.0000000000013719","article-title":"Trends and correlation between antibiotic usage and resistance pattern among hospitalized patients at university hospitals in Korea, 2004 to 2012: a nationwide multicenter study","volume":"97","author":"Kim","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jgar.2021.02.031_bib0013","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.2147\/IDR.S220183","article-title":"Time series analysis of antibacterial usage and bacterial resistance in China: observations from a tertiary hospital from 2014 to 2018","volume":"12","author":"Zeng","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2021.02.031_bib0014","first-page":"DC08","article-title":"Relationship between antimicrobial consumption and the incidence of antimicrobial resistance in Escherichia coli and Klebsiella pneumoniae isolates","volume":"9","author":"Joseph","year":"2015","journal-title":"J Clin Diagn Res"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2021.02.031_bib0015","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1007\/s40121-015-0081-y","article-title":"Considerations about antimicrobial stewardship in settings with epidemic extended-spectrum \u03b2-lactamase-producing or carbapenem-resistant Enterobacteriaceae","volume":"4","author":"Viale","year":"2015","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2021.02.031_bib0016","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/cid\/cix034","article-title":"The use of noncarbapenem \u03b2-lactams for the treatment of extended-spectrum \u03b2-lactamase infections","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.02.031_bib0017","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin\u2013tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2021.02.031_bib0018","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/mdr.2017.0266","volume":"24","author":"Shortridge","year":"2018","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2021.02.031_bib0019","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/jac\/dku025","article-title":"Ceftazidime\/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)","volume":"69","author":"Flamm","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.02.031_bib0020","doi-asserted-by":"crossref","first-page":"e00105","DOI":"10.1128\/AAC.00105-19","article-title":"Beyond piperacillin\u2013tazobactam: cefepime and AAI101 as a potent \u03b2-lactam\u2013\u03b2-lactamase inhibitor combination","volume":"63","author":"Papp-Wallace","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.02.031_bib0021","doi-asserted-by":"crossref","first-page":"e00514","DOI":"10.1128\/AAC.00514-19","article-title":"In vitro activity of cefepime\u2013enmetazobactam against Gram-negative isolates collected from United States and European hospitals during 2014\u20132015","volume":"63","author":"Morrissey","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.02.031_bib0022","series-title":"30th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)","first-page":"9975","article-title":"Outcomes of the novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination of cefepime\u2013enmetazobactam versus piperacillin\u2013tazobactam in adult patients with complicated urinary tract infections\u2014the ALLIUM phase 3 trial","author":"Kaye","year":"2020"},{"key":"10.1016\/j.jgar.2021.02.031_bib0023","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014tenth edition","year":"2015"},{"key":"10.1016\/j.jgar.2021.02.031_bib0024","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2020"},{"key":"10.1016\/j.jgar.2021.02.031_bib0025","doi-asserted-by":"crossref","first-page":"e00607","DOI":"10.1128\/JCM.00607-19","article-title":"Development of broth microdilution MIC and disk diffusion antimicrobial susceptibility test quality control ranges for the combination of cefepime and the novel \u03b2-lactamase inhibitor enmetazobactam","volume":"57","author":"Belley","year":"2019","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2021.02.031_bib0026","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 10, 2020. EUCAST; 2020."},{"key":"10.1016\/j.jgar.2021.02.031_bib0027","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.diagmicrobio.2015.03.025","article-title":"Characterization of extended-spectrum \u03b2-lactamases and antimicrobial resistance of Klebsiella pneumoniae in intra-abdominal infection isolates in Latin America, 2008\u20132012. Results of the Study for Monitoring Antimicrobial Resistance Trends","volume":"82","author":"Kazmierczak","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2021.02.031_bib0028","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1517\/14656566.2016.1154538","article-title":"Treatment options for extended-spectrum \u03b2-lactamase (ESBL) and AmpC-producing bacteria","volume":"17","author":"D'Angelo","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jgar.2021.02.031_bib0029","first-page":"E3463","article-title":"Global increase and geographic convergence in antibiotic consumption between 2000 and 2015","volume":"115","author":"Klein","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jgar.2021.02.031_bib0030","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.2147\/IDR.S180905","article-title":"Ceftolozane\/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy","volume":"12","author":"Escol\u00e0-Verg\u00e9","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2021.02.031_bib0031","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1586\/14787210.6.6.805","article-title":"Cefepime: a reappraisal in an era of increasing antimicrobial resistance","volume":"6","author":"Endimiani","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2021.02.031_bib0032","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/QCO.0000000000000623","article-title":"Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia","volume":"33","author":"Paterson","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jgar.2021.02.031_bib0033","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jama.2018.12565","article-title":"Carbapenem-sparing therapy for extended-spectrum \u03b2-lactamase-producing E. coli and Klebsiella pneumoniae bloodstream infection: the search continues","volume":"329","author":"Hayden","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2021.02.031_bib0034","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1093\/jac\/dkx181","article-title":"Sparing carbapenem usage","volume":"72","author":"Wilson","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.02.031_bib0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/antibiotics9020061","article-title":"Carbapenem-sparing strategies for ESBL producers: when and how","volume":"9","author":"Karaiskos","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2021.02.031_bib0036","article-title":"Association between minimum inhibitory concentration, \u03b2-lactamase genes and mortality for patients treated with piperacillin\/tazobactam or meropenem from the MERINO study","author":"Henderson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.02.031_bib0037","series-title":"Infectious Diseases Society of America guidance of the treatment of antimicrobial resistant Gram-negative infections","author":"Tamma","year":"2020"},{"key":"10.1016\/j.jgar.2021.02.031_bib0038","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/antibiotics8030122","article-title":"Present and future of carbapenem-resistant Enterobacteriaceae (CRE) infections","volume":"8","author":"Suay-Garc\u00eda","year":"2019","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2021.02.031_bib0039","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/1469-0691.12719","article-title":"The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide","volume":"20","author":"Nordmann","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2021.02.031_bib0040","doi-asserted-by":"crossref","first-page":"e00047","DOI":"10.1128\/CMR.00047-19","article-title":"Epidemiology of \u03b2-lactamase-producing pathogens","volume":"33","author":"Bush","year":"2020","journal-title":"Clin Microbiol Rev"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:56:36Z","timestamp":1761990996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521000643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":40,"alternative-id":["S2213716521000643"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.02.031","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016\u20132018 from USA and Europe: genotypic analysis of \u03b2-lactamases and comparative in vitro activity of cefepime\/enmetazobactam","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.02.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}